Comparative Pharmacology
Head-to-head clinical analysis: MAXAQUIN versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAQUIN versus ZAGAM.
MAXAQUIN vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
10-12 hours; prolonged in renal impairment
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic